文献速递糖尿病肥胖与代谢综合征

CagriSema对比司美格鲁肽或卡格列肽治疗2型糖尿病:REIMAGINE 2三期研究

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-06-07

安全性特征与GLP-1受体激动剂类及卡格列肽既往安全性数据一致。

要点

  • 研究纳入二甲双胍±SGLT2抑制剂治疗且BMI≥25 kg/m2的2型糖尿病患者。
  • 活性治疗组最常见不良事件为胃肠道疾病,安全性总体与既往数据一致。

核心结论

  • 其安全性特征与GLP-1受体激动剂类及卡格列肽既往安全性数据一致。

研究设计与样本

  • REIMAGINE 2为随机、双盲、安慰剂对照及活性药物对照、平行组3期研究,在30个国家开展。
  • 按8:8:2:8:8:1:1随机分配,疗程68周,主要终点为第68周HbA1c自基线变化(疗效估计)。

主要发现

  • 活性治疗组最常见不良事件为胃肠道疾病。

关键数值与推荐

  • 给药方式为每周一次皮下注射,疗程68周。
  • 安全性分析纳入至少接受一剂研究药物的全部参与者。

临床怎么用

  • 应用时需关注以胃肠道疾病为主的不良事件,其安全性特征与GLP-1受体激动剂类一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overweight or obesity. METHODS: REIMAGINE 2 was a randomised, double-blind, placebo-controlled and active-controlled, parallel-group study conducted in 30 countries (trial sites included university hospitals, health-care centres, research centres, and other centres). Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m2 or more, were randomly assigned (8:8:2:8:8:1:1) to receive once-weekly subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (hereafter cagrilintide-semaglutide [2·4 mg each]), semaglutide 2·4 mg, cagrilintide 2·4 mg, cagrilintide 1·0 mg plus semaglutide 1·0 mg (hereafter cagrilintide-semaglutide [1·0 mg each]), semaglutide 1·0 mg, or corresponding placebo for 68 weeks. Randomisation was done using a web-based system with blocked randomisation (block size 36) and stratification according to inclusion in the continuous glucose monitoring subgroup, HbA1c less than 8·5% at screening (yes or no), and country of participation (Japan; yes or no). The study participants, investigators, and study sponsor staff were masked to treatment allocation within dose level throughout the study. The primary endpoint was change in HbA1c from baseline to week 68 with cagrilintide-semaglutide (2·4 mg each) versus semaglutide 2·4 mg in the full analysis set; safety was assessed in all participants who received at least one dose of study product. This study is registered with ClinicalTrials.gov (NCT06065540) and is complete. FINDINGS: From Oct 10, 2023, to July 29, 2024, 3593 people were screened for eligibility, 2713 of whom were randomly assigned to cagrilintide-semaglutide (2·4 mg each; n=603), semaglutide 2·4 mg (n=605), cagrilintide 2·4 mg (n=152), cagrilintide-semaglutide (1·0 mg each; n=595), semaglutide 1·0 mg (n=609), or placebo (pooled 2·4 mg and 1·0 mg; n=149). 1164 (42·9%) of 2713 were female, 1549 (57·1%) were male, and 2207 (81·3%) were White. Of the randomly assigned participants, 2595 (95·7%) completed the study and 2376 (87·6%) were on treatment at week 68. Mean baseline HbA1c was 8·2% (SD 0·9). For the primary endpoint using the efficacy estimand, mean HbA1c change was significantly greater with cagrilintide-semaglutide (2·4 mg each) versus semaglutide 2·4 mg (-1·91 percentage points [SE 0·04] vs -1·75 percentage points [0·04]; estimated treatment difference -0·16 percentage points [95% CI -0·27 to -0·05]; p=0·0035). Adverse events were reported in 524 (86·9%) of 603 participants in the cagrilintide-semaglutide (2·4 mg each) group, 491 (81·2%) of 605 in the semaglutide 2·4 mg group, 125 (82·2%) of 152 in the cagrilintide 2·4 mg group, 485 (81·6%) of 594 in the cagrilintide-semaglutide (1·0 mg each) group, 477 (78·5%) of 608 in the semaglutide 1·0 mg group, and 105 (70·5%) of 149 in the placebo group. The most common adverse events in the active treatment groups were gastrointestinal disorders. INTERPRETATION: Cagrilintide-semaglutide (2·4 mg each) was superior to semaglutide 2·4 mg in reducing HbA1c in participants with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor. The safety profile of cagrilintide-semaglutide was consistent with the GLP-1 receptor agonist class and previous safety data for cagrilintide. These findings support the added benefit of cagrilintide-semaglutide (2·4 mg each) versus semaglutide 2·4 mg for glycaemic control. FUNDING: Novo Nordisk.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026. PMID: 42251859. doi:10.1016/S2213-8587(26)00125-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。